Jubilant Pharmova Limited posted a strong financial performance for the quarter ended December 31, 2024 (Q3 FY25), with a reported net profit of Rs 101 crore, marking a significant 52% year-on-year (YoY) increase compared to Rs 66 crore in Q3 FY24. The company’s improved profitability was driven by strong revenue growth across all business segments.
Key Financial Highlights for Q3 FY25:
- Revenue from operations: Rs 1,822 crore, up 9% YoY from Rs 1,677 crore in Q3 FY24.
- Total income: Rs 1,831 crore, reflecting a 7% growth from Rs 1,713 crore in Q3 FY24.
- EBITDA: Rs 296 crore, an 11% increase from Rs 267 crore in the same quarter last year.
- EBITDA margin: Expanded by 60 basis points to 16.2%, compared to 15.6% in Q3 FY24.
- Reported PAT: Rs 101 crore, up 52% from Rs 66 crore YoY.
- Normalized PAT: Rs 104 crore, up 57% YoY from Rs 66 crore.
The company attributed the strong earnings growth to improved performance in its CDMO Sterile Injectables, CRDMO, and Generics segments. The ramp-up of exports from the Roorkee facility and strategic partnerships in the biologics space contributed to the revenue increase.
Additionally, Jubilant Pharmova reduced its net debt significantly by repaying USD 125 million during the current financial year, leading to an improvement in the net debt-to-EBITDA ratio from 2.5x to 1.4x as of December 2024.
With ongoing expansion efforts, the company remains focused on profitability and operational efficiency, driven by growth in its radiopharmaceutical and drug discovery segments.